Renalase Deficiency in Heart Failure Model of Rats—A Potential Mechanism Underlying Circulating Norepinephrine Accumulation by Gu, Rong et al.
Renalase Deficiency in Heart Failure Model of Rats—A
Potential Mechanism Underlying Circulating
Norepinephrine Accumulation
Rong Gu, Wen Lu, Jun Xie, Jian Bai, Biao Xu*
Department of Cardiology, Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing, China
Abstract
Background: Sympathetic overactivity and catecholamine accumulation are important characteristic findings in heart
failure, which contribute to its pathophysiology. Here, we identify a potential mechanism underlying norepinephrine
accumulation in a rat model of heart failure.
Methodology/Principal Findings: Initially, we constructed a rat model of unilateral renal artery stenosis (n=16) and found
that the expression of renalase, a previously identified secreted amine oxidase, was markedly reduced in the ischemic
compared to the non-ischemic kidney (protein: 0.29560.085 versus 0.76560.171, p,0.05). Subsequently, we utilized an
isolated perfused rat kidney model to demonstrate that the clearance rate of norepinephrine decreased with reduction of
perfusion flow. On the basis of these findings, we hypothesized the reduced renal blood supply which occurs in heart failure
would result in impaired synthesis of renalase by the kidney and consequently reduced degradation of circulating
norepinephrine. To verify this, we used a rat model of infarction-induced heart failure (n=12 per group). In these rats, the
flow velocity of renal artery, when measured at four weeks, is obviously lower in the operation group. Renal expression of
renalase was reduced (protein: 0.47660.043 for control, 0.24860.029 for operation versus 0.63660.151 for sham-operation)
and this was associated with an increase in circulating norepinephrine (0.16860.016 ng/mL for control, 0.20360.019 ng/mL
for operation versus 0.13860.008 ng/mL for sham-operation).
Conclusions/Significance: Renalase expression is influenced by renal blood flow and impaired synthesis of renalase by the
kidney may represent a potential mechanism underlying circulating norepinephrine accumulation in heart failure.
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Introduction
Chronic heart failure occurs as a result of a variety of
cardiovascular diseases, the most common being is ischemic heart
disease and in particular myocardial infarction. It carries a poor
prognosis, worse than that of malignant tumors collectively [1].
One of the most important pathophysiologic characteristics of
heart failure is sympathetic overactivity [2], which can contribute
to the progression and pathophysiology of cardiac dysfunction.
The plasma concentration of catecholamines is higher in patients
with heart failure than in controls [3], and the degree of elevation
is inversely correlated with prognosis [4].
In the context of end-stage heart failure, levels of circulating
catecholamines may be extremely high, whilst they are diminished
within the tissues especially the myocardium [5]. This paradox is
mainly explained by decreased tissue uptake and hence clearance
of plasma norepinephrine [6]. However, the mechanism under-
lying this decrease in catecholamine clearance remains largely
unclear. Catecholamines are mainly metabolized by the enzymes
monoamine oxidase and catechol-o-methyl transferase. However,
these two enzymes are both located intracellularly, so that they
cannot degrade circulating catecholamines directly but only target
them either before release from the nerve terminal or once they
have been taken up by cells through one of the catecholamine
uptake mechanisms.
Renalase, a renally synthesized protein mainly expressed in the
glomeruli and proximal tubules, was identified as an amine
oxidase in 2005 [7]. Unlike the classical amine oxidases, renalase is
a secreted enzyme which can be detected in plasma and degrades
circulating catecholamines. Plasma renalase is markedly reduced
in chronic renal failure and nephrectomized rats, and this
reduction is accompanied by a sizeable increase in circulating
concentrations of catecholamines [8]. Renalase-treated animals
exhibit a large reduction in blood pressure accompanied by a
decreased concentration of circulating catecholamines [7].
We hypothesized that reduced blood supply to the kidney, as a
result of redistribution of peripheral blood flow in heart failure,
causes suppression of renalase synthesis and consequently reduced
degradation of circulating catecholamines. The aims of the present
study were therefore: (a) to evaluate the influence of renal blood
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model; (b) to ascertain the relationship between renal perfusion
flow and renal metabolism of norepinephrine using an in vitro
kidney perfusion model; and (c) to investigate the relationship
between the expression and activity of renalase in the kidney and
the plasma as well as the concentration of plasma norepinephrine
in an animal model of heart failure. Our studies focused on
norepinephrine rather than epinephrine, since the former appears
to exert much more important effects both on the heart and
vasculature than the latter, at concentrations found in the
circulation both in health and in the context of heart failure.
Methods
Animal model of unilateral renal artery stenosis
To investigate whether renal blood flow has influence on renal
synthesis of renalase, rats model of unilateral renal artery stenosis
was constructed, as detailed in Methods S1.
Norepinephrine metabolism by the kidney in vitro
To investigate whether norepinephrine can be degraded
directly by the kidney, and whether perfusion flow or pressure
can influence its clearance rate, we constructed isolated perfused
rat kidney model as previously described [9,10]. Full details are
given in Methods S1. Norepinephrine was added to the Krebs-
Henseleit bicarbonate perfusate, adjusting the concentration to
20 ng/mL.
Animal model of acute myocardial infarction (AMI)
To evaluate the expression and activity of renalase and the
concentration of plasma norepinephrine in animals with cardiac
dysfunction, a rat AMI model (n=12/group) was constructed as
previously described [11], as detailed in Methods S1.
All animal research conformed to the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised 1985)
and was approved by the Ethics Review Board for Animal Studies
of Nanjing Drum Tower Hospital (DTH ERBA 66.01/037D/
2009).
Renalase activity
Amine oxidase activity of renalase in the perfusate and plasma
of heart failure rats was measured by Amplex Red Monoamine
Oxidase Assay Kit (Invitrogen), based on the detection of H2O2 in
a horseradish peroxidase-coupled reaction according to the
manufacturer’s instructions.
Renal blood flow velocity
To evaluate renal blood flow of different groups in heart failure
model, the renal blood flow velocity were detected using Toshiba
Xario ultrasound system (SSA-680) with a 7.5 MHz linear-array
transducer. The flow velocity of renal artery proximal to
abdominal aorta of different groups were evaluated by a
technician blinded to the grouping.
Echocardiography and hemodynamic assessment
To evaluate cardiac function of rats post-AMI, we performed
echocardiography and hemodynamic assessment four weeks after
LAD ligation. Full details of the methodology are given in
Methods S1.
Plasma and tissue sample preparation
Full details are given in Methods S1.
Plasma brain natriuretic peptide (BNP) quantification
We measured plasma BNP concentration using a commercially
available kit (Uscn Life Science Inc. Wuhan, China)following the
manufacturer’s instructions.
Renalase protein expression in the kidney
Renalase protein expression in the kidney was quantified by
western blotting, and alpha-tubulin was also quantified in the same
samples as control. Full details of the methodology are given in
Methods S1. Results were presented as density values of renalase
as a ratio to alpha-tubulin.
Norepinephrine quantitation by EIA
Plasma, perfusate and urinary norepinephrine concentration
were determined by competitive ELISA using a commercially
Figure 1. Protein expression of renalase diminished in the ischemic compared to the non-ischemic kidney. A, There is no statistic
difference between renalase expression between the ACEI and control groups both in the ischemia kidney and the nonischemia one. B, Western
blotting showing renalase protein expression of ischemia kidney is lower than that of the nonischemia one. Alpha-tubulin also shown as a
housekeeping control. Corresponding graph shows accumulated results from n=8 (A) or n=16 (B) for each group (0.29560.085 versus 0.76560.171).
*p,0.01 vs. ischemic kidney. NS: No statistical difference is existed between the two groups.
doi:10.1371/journal.pone.0014633.g001
Renalase and Heart Failure
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e14633Figure 2. Norepinephrine clearance is decreased in the hypoperfused kidney. A, Concentration of norepinephrine at different time points in
the perfusion medium, using a perfusion flow rate of 10 mL/min. B, Clearance rate of norepinephrine at conditions of different perfusion flow. In the
hypoperfusion group, the perfusion flow rate is 10 mL/min for the initial 30 min, followed by 5 mL/min for the succeeding 60 min. In the control group,
the perfusion flow rate is constant at 10 mL/min for 90 min. *P,0.01 vs. control. C, Dose-response curve analysis (renal flow/norepinephrine clearance)
in isolated perfused rat kidney model. The norepinephrine clearance is increased with increment in perfusion flow below 10mL/min while the clearance
remained stable at 15mL/min as compared with 10mL/min. D, Renalase activity and concentration in the perfusate at different time points during the
perfusion. The activity and concentration are undetectable at time 0. But within 10 minutes of the initiation of norepinephrine perfusion, renalase
activity and concentration increased significantly and remained high after 20 minutes during the perfusion procedure. n=5 per group.
doi:10.1371/journal.pone.0014633.g002
Figure 3. The flow velocity of renal artery is obviously lower in the operation group of heart failure model. A, Ultrasonic images of
renal artery flow velocity of different groups. B, Corresponding graph shows accumulated results of flow velocity from n=12 for each group
(21.9362.40 cm/s for control, 12.4360.82 cm/s for operation versus 20.3561.76 cm/s for sham-operation). *p,0.05 vs. sham-operation, p,0.05 vs.
control.
doi:10.1371/journal.pone.0014633.g003
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manufacturer’s instructions.
Determination of plasma and perfusate renalase
concentration
Plasma and perfusate renalase concentration was determined by
ELISA analysis, full details are given in Methods S1.
Immunohistochemical analysis of renalase expression in
the kidney
We carried out immunohistochemical analysis to determine
renalase expression and spatial distribution in the kidney. 5um
paraffin-embedded kidney slices were incubated with anti-renalase
antibody (1:300, Abcam) at 4uC overnight, and visualized using
EnVision detection system with peroxidase/DAB (DAKO).
Renalase expression was quantified using Image Pro Plus 6.0
software (Media Cybernetics).
Statistical analysis
All results are expressed as mean 6 SEM. Comparisons
between two groups (ischemia and nonischemia in renal artery
stenosis model) were performed by Wilcoxon rank sum test, while
comparisons of data among three groups (operation, sham-
operation and control in heart failure model) were performed by
Kruskal-Walls test. All data were analysed using SPSS 13.0
software (SPSS, Inc, Chicago, IL, USA). Statistical significance
was defined as P,0.05 (two-tailed).
The authors had full access to the data and take responsibility
for its integrity. All authors have read and agree to the manuscript
as written.
Results
Protein expression of renalase in renal ischemia model
No difference was found in renalase protein expression between
rats treated with angiotensin converting-enzyme inhibitor (ACEI)
and those treated with corresponding vehicle (n=8/group;
Table 1. Physical characteristics and cardiac function evaluation of rats 4 weeks post-LAD ligation.
heart weight/
body weight
(%) BNP (pg/mL) LVEDD (cm) LVESD (cm) FS (%) HR (bpm)
LVEDP
(mmHg)
±dp/dtmax
(mmHg/s)
Operation 3.7160.41 83.17612.46 0.71260.082 0.53960.066 23.38062.941 225.54665.993 23.4262.16 6(834.56612.33)
Sham-operation 2.9360.20* 17.3963.13** 0.58160.078* 0.34860.046* 39.89061.616* 208.80068.576 5.8261.27* 6(2310.45621.58)*
Control 2.8960.23* 16.2962.96** 0.51060.030
** 0.29360.021
** 42.43061.512
** 210.29066.059 3.2161.14* 6(2834.27619.35)*
*p,0.05 vs. operation,
**p,0.01 vs. operation.
doi:10.1371/journal.pone.0014633.t001
Figure 4. Protein expression of renalase is decreased in
kidneys from heart failure rats four weeks after LAD ligation.
Alpha-tubulin also shown as a housekeeping control. Corresponding
graph shows accumulated results from n=12 for each group
(0.47660.043 for control, 0.24860.029 for operation versus
0.63660.151 for sham-operation). *p,0.01 vs. sham-operation,
p,0.01 vs. control.
doi:10.1371/journal.pone.0014633.g004
Figure 5. Renalase expression in the kidney increases and
subsequently decreases with progression of heart failure post-
LAD ligation. Western blot showing expression of renalase at different
timepoints(24 h–4weeks)post-LADligation.Alpha-tubulinexpressionis
also shown as a housekeeping control. Corresponding graph shows
accumulated results from n=4 for each time point (1.22360.086 for 24h,
1.55660.102 for 1w, 0.98760.056 for 2w, 1.11260.057 for 3w,
0.94560.078 for 4w). * p,0.05 vs. 24h, 2w, 3w and 4w. ** p,0.05 vs. 24h.
doi:10.1371/journal.pone.0014633.g005
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angiotensin-aldosterone system activity could potentially influence
renalase expression. On the other hand, as shown in Figure 1b,
protein expression levels was lower in the ischemic than the non-
ischemic kidney, indicating that renal blood flow has an important
influence on renal synthesis of renalase.
Catecholamine degradation by the isolated perfused
kidney
The concentration of norepinephrine in the perfusion medium
decreased gradually during perfusion (Figure 2A). Moreover, the
clearance rate of norepinephrine decreased with reduction of
either perfusion flow or pressure (Figure 2B). As shown in
Figure 2C, dose-response curve analysis (renal flow/norepineph-
rine clearance) were performed. The norepinephrine clearance is
increased with increment in perfusion flow below 10mL/min
while the clearance remained stable at 15mL/min as compared
with 10mL/min. We also obtained measurements of creatinine
clearance at the same time, and these confirmed that the isolated
kidney exhibited good function in every case (data not shown). The
data suggest that norepinephrine can be degraded directly by the
kidney, and that perfusion flow or pressure are important factors
influencing its clearance rate.
Renalase activity
As shown in Figure 2D, renalase activity in the perfusate is
undetectable at time 0. But within 10 minutes of the initiation of
norepinephrine perfusion, renalase activity increased significantly
and remained high after 20 minutes during the perfusion
procedure. Unfortunately, we can not find the direct correlation
between norepinephrine clearance and renalase activity in our
experiment. Meanwhile, we also noticed that the elevation of
renalase activity in the initial 20 minutes is most likely due to the
increased renalase concentration in the perfusate as a result of
renalase secretion by the kidney in this time course. In heart failure
model, the plasma renalase activity is *9168AU in operation
group, 4667AU in sham-operation group while 3567AU in
control group. (*p,0.05 vs. sham-operation, p,0.05 vs. control.)
Perfusate renalase concentration. As shown in figure 2D,
renalase concentration in the perfusate is undetectable at time 0
while after the initiation of norepinephrine perfusion, it rose
significantly and remained at a relative high level 20 minutes post-
perfusion.
Renal blood flow velocity
As shown in Figure 3, the flow velocity of renal artery is
obviously lower in the operation group as compared to both
control and sham-operation groups in heart failure model
(21.9362.40 cm/s for control, 12.4360.82 cm/s for operation
versus 20.3561.76 cm/s for sham-operation).
Physical characteristics and cardiac function
Heart weight/body weight (%) and plasma BNP concentration
were both higher in operation group compared to the other two
groups, indicating progressive ventricular remodeling and elevated
cardiac loading. As expected, systolic function, evaluated by %FS
and 6dp/dt, exhibited a marked deterioration in the operation
group compared with the sham operation and control groups
(Table 1). Heart rate was slightly higher in the operation group,
consistent with heightened sympathetic activity, although this rise
did not reach statistical significance. Additionally, LVESD,
LVEDD and LVEDP were both higher in operation animals
compared to the other two groups, while no differences were seen
among the three groups in IVSd or LVPWT (data not shown).
Protein expression of renalase in heart failure rats
Renalase expression decreased at the protein level in the kidneys
of heart failure rats compared with those of control rats (Figure 4).
To determine the time course of changes in renalase expression
in the kidneys, this was determined by western blotting at different
time points (24 h–4 weeks) following LAD ligation. Renal renalase
expression increased and reached a peak at one week post-LAD
ligation, gradually decreasing thereafter (Figure 5).
Plasma norepinephrine and renalase concentrations
Plasma norepinephrine was higher in heart failure rats than the
other two groups (Figure 6A), confirming sympathetic overactivity
and catecholamine accumulation as a result of heart failure.
Plasma renalase was elevated in operation as compared to both
sham operation and control rats (Figure 6B). We also analyzed the
correlation between renalase expression in kidney and plasma
levels of norepinephrine (r=20.485, p=0.110) or the correlation
between plasma concentration of renalase and norepinephrine
(r=20.532, p=0.075) at 4 weeks following LAD ligation,
although which showed no statistical significance, the tendency
of the higher renalase, the lower norepinephrine did exist in heart
failure rats (data not shown).
Figure 6. Plasma norepinephrine and renalase concentrations are both increased in heart failure rats. A, Plasma norepinephrine
concentration in different groups (0.16860.016 ng/mL for control, 0.20360.019 ng/mL for operation versus 0.13860.008 ng/mL for sham-operation).
B, Plasma renalase concentration in different groups (0.53560.109 ug/mL for control, 1.14460.243 ug/mL for operation versus 0.87260.171 ug/mL
for sham-operation). n=12 per group. *p,0.05.
doi:10.1371/journal.pone.0014633.g006
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The spatial distribution of renalase within the kidney was
mainly in proximal tubules, with much weaker expression in
glomeruli. Quantitative analysis showed a reduction of renalase
expression in the kidneys of heart failure rats (Figure 7A–7H),
consistent with the results of protein expression as determined by
western blotting.
Discussion
Sympathetic neurohormonal overactivity and consequent
accumulation of circulating catecholamines are characteristically
found in heart failure. Sustained sympathetic activation leads to
further deterioration of cardiac function through a variety of
mechanisms including stimulation of cardiomyocyte apoptosis
[12], direct toxicity to cardiomyocytes [13], and induction of
ventricular dysrhythmias [14]. In the present study, we tried to
explore the mechanism underlying circulating norepinephrine
accumulation in heart failure with the finding that renalase protein
expression was impaired in the ischemia kidney as compared to
the non-ischemia one. In the isolated perfused kidney model, we
found that the norepinephrine can be degraded directly by the
kidney and as blood flow or pressure declined, the rate of
clearance of norepinephrine decreased in parallel. In the kidneys
of rats with ischemia-induced heart failure, we found that the flow
velocity of renal artery and renalase protein expression were
reduced with a concomitant increased concentration of circulating
norepinephrine.
The catecholamine accumulation which occurs in this context
may in part be explained by desensitization of arterial baroreflexes
Figure 7. Renalase expression is reduced in the kidneys of heart failure rats. Renalase expression is demonstrated immunohistochemically
in kidney cortex (A–C) and medulla (D–F). A, D, Control. B, E, Operation. C, F, Sham-operation. G–H, Quantification of renalase expression in
different groups in renal cortex (G) and medulla (H). n=12 per group. *p,0.01. Scale bars: 100 mm(A–F).
doi:10.1371/journal.pone.0014633.g007
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and circulating levels of angiotensin II [17–20]. However, this is
unlikely to be the full explanation since, with increasing
sympathetic activation, norepinephrine becomes depleted in the
nerve terminals. We considered it likely, therefore, that norepi-
nephrine metabolism is also decreased in heart failure. The
present results show that, indeed, heart failure is associated with a
decrease in renalase expression by the kidney, which in turn causes
a decrease in norpeinephrine degradation and hence its accumu-
lation in the circulation.
Unlike MAO-A and MAO-B, renalase is secreted into the blood
and metabolizes catecholamines in the circulation [7]. Moreover,
circulating renalase is largely inactive under basal conditions (in
the form of prorenalase), while excess catecholamines not only
stimulate its activity (through conversion to renalase) but also
upregulate its synthesis and secretion [8]. Two single nucleotide
polymorphisms (SNPs) of the renalase gene (rs2576178 and
rs2296545) have been shown to be associated with essential
hypertension in a north Han Chinese population [21]. Renalase
protein expression is decreased in the hearts of neonatally
nephrectomized rats compared to those of control animals, and
this has been postulated to contribute to the increase in plasma
norepinephrine in these rats [22].
In the present study, we found in a unilateral renal artery
stenosis rat model that the synthesis of renalase by the ischemic
kidney was impaired compared to the non-ischemic kidney,
suggesting that renal blood flow has an important influence on
renalase synthesis by the kidney. This may to a large extent explain
the circulating renalase deficiency seen in patients with end-stage
kidney disease. In the kidneys of rats with experimentally-induced
heart failure, we found that the flow velocity of renal artery is
obviously lower. Unfortunately, we can not obtain the exact data
of diameter of renal artery or that of blood flow in view of the
limitation of the resolution of our measurement instrument. But
considering the similar renal artery diameter of rats of the same
age, we believe that the renal flow velocity could at least in part
represent the situation of renal blood flow. That is to say, the renal
blood flow is lower in the operation group compared to the other
two groups. Renalase protein expression was reduced with a
concomitant increased concentration of circulating norepineph-
rine in our post-MI heart failure model.
It has previously been demonstrated that plasma renalase is
inactive whilst urinary renalase has amine oxidase activity under
basal conditions [8]. This, coupled with the finding that
catecholamines can activate renalase [8], suggests two possibilities:
either renalase does not exert a physiologically important function
or catecholamines can be metabolized by renalase in the kidney
rather than by circulating renalase, under basal conditions in vivo.
To distinguish between these two possibilities, we investigated
norepinephrine clearance in the isolated kidney perfusion model.
Our results strongly support the notion that norepinephrine is
directly degraded by the kidney. Importantly we found that, as
blood flow or pressure declined, the rate of clearance of
norepinephrine decreased in parallel. But as there is no clear
evidence that this rapid effect is due to lack of renalase, further
investigation on possible mechanism of such a rapid effect is
needed.
Interestingly, the plasma renalase concentration was higher in
heart failure rats compared with control animals. In the same way
as sympathoadrenal activity changes from compensation in the
early phase to decompensation in the late phase of heart failure,
we hypothesized that renalase expression in vivo goes through
similar changes as the function of heart failure progression. To
confirm our hypothesis, immunoblotting analysis of renalase
expression in the kidney was undertaken at different time points
following LAD ligation. Intriguingly, we found that renalase
protein level increased to a peak at one week, declining thereafter
to reach sub-basal levels. It has previously been demonstrated that
circulating catecholamines are elevated [3] whilst renal blood flow
is decreased, in patients with asymptomatic left ventricular
dysfunction [23]. We therefore propose that the kidney may
synthesize and secrete more renalase to compensate for the
increase in catecholamine concentration, during the early stage of
deterioration of cardiac function and as cardiac function continues
to deteriorate, renal blood flow falls to a critical level, so that
renalase expression by the kidney fails to keep up with the increase
in catecholamines, resulting in a phase of decompensation.
However, the mechanism underlying renalase deficiency in
under-perfused kidney remains largely unknown. Both anoxia
and renal cell insult could be the reason, which needs further
investigation.
Also, we found that the concentration and activity of plasma
renalase were both higher in heart failure rats so that there was
more activated renalase to degrade the increased circulating
catecholamine in heart failure rats which is in favor of our
hypothesis.
However, in the present study we do not provide direct evidence
for a causal relationship between the increase in plasma
norepinephrine of heart failure rats and reduced norepinephrine
degradation by renalase, which needs further investigation.
Nevertheless, our data indicate that renalase deficiency may
represent a potential mechanism underlying catecholamine
accumulation in heart failure. It remains to be seen whether
renalase replacement may prove to be a promising therapy for
heart failure.
Supporting Information
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